Heat Biologics, Inc. (HTBX)
Chart Events
Performance Outlook
| Previous Close | 7.09 |
| Open | 6.96 |
| Bid | 6.95 x 900 |
| Ask | 7.00 x 1000 |
| Day's Range | 6.80 - 7.14 |
| 52 Week Range | 1.40 - 30.10 |
| Volume | 803,839 |
| Avg. Volume | 1,356,664 |
| Market Cap | 157.328M |
| Beta (5Y Monthly) | 0.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings Date | Aug 07, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.25 |
- ACCESSWIRE
Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021
DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B.
- ACCESSWIRE
Heat Biologics Commences Manufacturing Process for ZVX-60
DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc.Jeff Wolf, Heat's CEO, commented, "Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical trials.
- ACCESSWIRE
Heat Biologics Promotes William L. Ostrander to Chief Financial Officer
DURHAM, NC / ACCESSWIRE / January 11, 2021 /Heat Biologics, Inc. ("Heat")(NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021.
